FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022246614> ?p ?o ?g. }

• W2022246614 abstract "Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DCThe insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) are transmembrane receptor tyrosine kinases that serve as key regulators of the IGF signaling axis. Activation of IGF-1R and IR results in proliferative and antiapoptotic effects via the ERK and PI3K/AKT pathways. Activated IGF-1R and IR also directly affect glucose metabolism by decreasing gluconeogenesis, increasing glycogen formation and increasing translocation of GLUT transporters, thereby increasing overall glucose uptake in tissues. Dysregulated IGF-1R/IR signaling has been implicated in many human cancers and has been implicated in resistance to anticancer therapies including cytotoxic chemotherapy, hormonal agents and radiation therapy. IGF-1R/IR overexpression has been demonstrated in several tumor types including breast, prostate, lung, ovarian and colon cancers. Moreover, increased activation and overexpression of IGF-1R/IR is associated with an increased propensity for invasion and metastasis correlating with poor survival. Consequently, IGF-1R and IR have been identified as attractive targets for the generation of novel anticancer agents. OSI-906 is a potent and selective dual inhibitor of IGF-1R/IR and is currently in clinical development. The radiotracer [18F]-FDG is used clinically to stage disease or monitor treatment response by virtue of measuring glucose uptake as a surrogate for metabolic activity in tumors. Since IGF-1R and IR signaling directly affect glucose metabolism we evaluated the utility of [18F]-FDG-PET as a potential means to non-invasively monitor pharmacodynamic (PD) effects for OSI-906. In vitro the IGF-1R/IR positive cell line, H292, responded rapidly to OSI-906 treatment by significantly reducing uptake of 3H-glucose. Radiotracer uptake was inhibited in a dose dependent manner and occurred within minutes of drug treatment correlating with inhibition of the IGF-1R/IR pathways and other downstream signaling events. In vivo xenografts bearing the same cell line demonstrated significantly reduced uptake of [18F]-FDG at 2 and 4 hours post treatment which correlated with substantial (>80%) target inhibition of both phospho-IGF1-R and phospho-IR in the tumor lysates. Western blot analysis of in vivo tumor lysates confirmed significant inhibition of phospho-AKT and other markers associated with altered glycolysis. In contrast, in the IGF-1R/IR-negative H441 xenograft model no significant change in uptake of [18F]-FDG was observed over the same time course. Our data indicate that [18F]-FDG-PET may serve as a rapid, non-invasive PD marker for OSI-906 in the clinical setting where accurate assessment of PD effects is often limited by the lack of readily accessible tumor samples.Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 5244." @default.
• W2022246614 created "2016-06-24" @default.
• W2022246614 creator A5005688348 @default.
• W2022246614 creator A5028063270 @default.
• W2022246614 creator A5038223232 @default.
• W2022246614 creator A5043541334 @default.
• W2022246614 creator A5051575647 @default.
• W2022246614 creator A5053593549 @default.
• W2022246614 creator A5080775024 @default.
• W2022246614 date "2010-04-15" @default.
• W2022246614 modified "2023-09-25" @default.
• W2022246614 title "Abstract 5244: Preclinical, real-time assessment of early pharmacodynamic effects for the IGF-1R/IR inhibitor OSI-906 by [18F]-FDG-PET" @default.
• W2022246614 doi "https://doi.org/10.1158/1538-7445.am10-5244" @default.
• W2022246614 hasPublicationYear "2010" @default.
• W2022246614 type Work @default.
• W2022246614 sameAs 2022246614 @default.
• W2022246614 citedByCount "0" @default.
• W2022246614 crossrefType "proceedings-article" @default.
• W2022246614 hasAuthorship W2022246614A5005688348 @default.
• W2022246614 hasAuthorship W2022246614A5028063270 @default.
• W2022246614 hasAuthorship W2022246614A5038223232 @default.
• W2022246614 hasAuthorship W2022246614A5043541334 @default.
• W2022246614 hasAuthorship W2022246614A5051575647 @default.
• W2022246614 hasAuthorship W2022246614A5053593549 @default.
• W2022246614 hasAuthorship W2022246614A5080775024 @default.
• W2022246614 hasConcept C101544691 @default.
• W2022246614 hasConcept C126322002 @default.
• W2022246614 hasConcept C134018914 @default.
• W2022246614 hasConcept C170493617 @default.
• W2022246614 hasConcept C185592680 @default.
• W2022246614 hasConcept C2777866211 @default.
• W2022246614 hasConcept C2779306644 @default.
• W2022246614 hasConcept C502942594 @default.
• W2022246614 hasConcept C55493867 @default.
• W2022246614 hasConcept C62478195 @default.
• W2022246614 hasConcept C71924100 @default.
• W2022246614 hasConcept C75217442 @default.
• W2022246614 hasConcept C86554907 @default.
• W2022246614 hasConcept C98274493 @default.
• W2022246614 hasConceptScore W2022246614C101544691 @default.
• W2022246614 hasConceptScore W2022246614C126322002 @default.
• W2022246614 hasConceptScore W2022246614C134018914 @default.
• W2022246614 hasConceptScore W2022246614C170493617 @default.
• W2022246614 hasConceptScore W2022246614C185592680 @default.
• W2022246614 hasConceptScore W2022246614C2777866211 @default.
• W2022246614 hasConceptScore W2022246614C2779306644 @default.
• W2022246614 hasConceptScore W2022246614C502942594 @default.
• W2022246614 hasConceptScore W2022246614C55493867 @default.
• W2022246614 hasConceptScore W2022246614C62478195 @default.
• W2022246614 hasConceptScore W2022246614C71924100 @default.
• W2022246614 hasConceptScore W2022246614C75217442 @default.
• W2022246614 hasConceptScore W2022246614C86554907 @default.
• W2022246614 hasConceptScore W2022246614C98274493 @default.
• W2022246614 hasLocation W20222466141 @default.
• W2022246614 hasOpenAccess W2022246614 @default.
• W2022246614 hasPrimaryLocation W20222466141 @default.
• W2022246614 hasRelatedWork W1503731208 @default.
• W2022246614 hasRelatedWork W1550382084 @default.
• W2022246614 hasRelatedWork W2033767772 @default.
• W2022246614 hasRelatedWork W2036596700 @default.
• W2022246614 hasRelatedWork W2092273440 @default.
• W2022246614 hasRelatedWork W2097977881 @default.
• W2022246614 hasRelatedWork W2099063182 @default.
• W2022246614 hasRelatedWork W2120093145 @default.
• W2022246614 hasRelatedWork W2125251091 @default.
• W2022246614 hasRelatedWork W2155941706 @default.
• W2022246614 hasRelatedWork W2156261378 @default.
• W2022246614 hasRelatedWork W2188401602 @default.
• W2022246614 hasRelatedWork W2315780822 @default.
• W2022246614 hasRelatedWork W2337848185 @default.
• W2022246614 hasRelatedWork W2525984156 @default.
• W2022246614 hasRelatedWork W2560157215 @default.
• W2022246614 hasRelatedWork W2567303633 @default.
• W2022246614 hasRelatedWork W2947068524 @default.
• W2022246614 hasRelatedWork W3035314213 @default.
• W2022246614 hasRelatedWork W3162141400 @default.
• W2022246614 isParatext "false" @default.
• W2022246614 isRetracted "false" @default.
• W2022246614 magId "2022246614" @default.
• W2022246614 workType "article" @default.